UBS Group Cuts Charles River Laboratories Intl. (NYSE:CRL) Price Target to $145.00

Charles River Laboratories Intl. (NYSE:CRL) had its target price trimmed by UBS Group from $147.00 to $145.00 in a research note released on Thursday morning, Stock Target Advisor reports. The brokerage currently has a neutral rating on the medical research company’s stock.

A number of other research firms also recently weighed in on CRL. Zacks Investment Research downgraded Charles River Laboratories Intl. from a buy rating to a hold rating in a research report on Monday, October 21st. Credit Suisse Group set a $138.00 price target on Charles River Laboratories Intl. and gave the stock a hold rating in a research report on Friday, September 13th. SunTrust Banks upped their price target on Charles River Laboratories Intl. from $156.00 to $162.00 and gave the stock a buy rating in a research report on Monday, September 16th. ValuEngine downgraded Charles River Laboratories Intl. from a buy rating to a hold rating in a research report on Thursday, August 1st. Finally, Bank of America downgraded Charles River Laboratories Intl. from a buy rating to a neutral rating and set a $150.00 price target for the company. in a research report on Friday, October 18th. Eight investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The company presently has an average rating of Buy and an average price target of $150.50.

NYSE:CRL traded up $3.14 during trading hours on Thursday, reaching $130.51. 318,713 shares of the stock were exchanged, compared to its average volume of 360,739. Charles River Laboratories Intl. has a twelve month low of $103.00 and a twelve month high of $149.07. The company has a debt-to-equity ratio of 1.47, a current ratio of 1.59 and a quick ratio of 1.38. The firm has a 50 day moving average of $132.15 and a 200 day moving average of $133.41. The stock has a market cap of $6.23 billion, a PE ratio of 21.64, a PEG ratio of 2.00 and a beta of 1.08.

Charles River Laboratories Intl. (NYSE:CRL) last released its quarterly earnings results on Wednesday, November 6th. The medical research company reported $1.69 earnings per share for the quarter, topping analysts’ consensus estimates of $1.64 by $0.05. Charles River Laboratories Intl. had a return on equity of 22.01% and a net margin of 8.94%. The firm had revenue of $668.00 million during the quarter, compared to the consensus estimate of $674.08 million. During the same quarter in the prior year, the firm posted $1.53 EPS. The business’s revenue was up 14.1% on a year-over-year basis. Equities research analysts anticipate that Charles River Laboratories Intl. will post 6.53 earnings per share for the current year.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

In other news, insider David Ross Smith sold 1,249 shares of the company’s stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $130.36, for a total transaction of $162,819.64. Following the sale, the insider now owns 19,327 shares in the company, valued at approximately $2,519,467.72. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 1.80% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. raised its stake in Charles River Laboratories Intl. by 1.6% in the 2nd quarter. BlackRock Inc. now owns 4,660,628 shares of the medical research company’s stock valued at $661,344,000 after acquiring an additional 72,827 shares during the period. AQR Capital Management LLC raised its stake in Charles River Laboratories Intl. by 7.5% in the 2nd quarter. AQR Capital Management LLC now owns 2,239,921 shares of the medical research company’s stock valued at $317,845,000 after acquiring an additional 157,160 shares during the period. TimesSquare Capital Management LLC raised its stake in Charles River Laboratories Intl. by 11.0% in the 3rd quarter. TimesSquare Capital Management LLC now owns 1,007,750 shares of the medical research company’s stock valued at $133,396,000 after acquiring an additional 99,900 shares during the period. Bank of New York Mellon Corp raised its stake in Charles River Laboratories Intl. by 49.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 978,183 shares of the medical research company’s stock valued at $138,804,000 after acquiring an additional 323,625 shares during the period. Finally, Bank of America Corp DE raised its stake in Charles River Laboratories Intl. by 5.1% in the 2nd quarter. Bank of America Corp DE now owns 471,966 shares of the medical research company’s stock valued at $66,972,000 after acquiring an additional 22,821 shares during the period. Institutional investors and hedge funds own 94.31% of the company’s stock.

About Charles River Laboratories Intl.

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Recommended Story: What is the price-sales ratio?

Analyst Recommendations for Charles River Laboratories Intl. (NYSE:CRL)

Leave a Reply

Your email address will not be published. Required fields are marked *

*